Who
Brian Piper
EVP, Chief Financial Officer
Company insider
Files Form 4 as: EVP, Chief Financial Officer, Sana Biotechnology; Chief Financial Officer, Prelude Therapeutics; CFO & Corporate Secretary, Aevi Genomic Medicine.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $563K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 15 Apr 2016
- Last trade
- 17 Feb 2026
- Last filed
- 18 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Feb 2026filed 18 Feb 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 25 Aug 2021filed 27 Aug 2021 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,333 at $0.00 | filing |
| 25 Aug 2021filed 27 Aug 2021 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Code M | $16K8,333 at $1.89 | filing |
| 25 Aug 2021filed 27 Aug 2021 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Sold | $68K2,100 at $32.44 | filing |
| 25 Aug 2021filed 27 Aug 2021 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Sold | $129K3,889 at $33.23 | filing |
| 25 Aug 2021filed 27 Aug 2021 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Sold | $80K2,344 at $34.33 | filing |
| 20 Jul 2021filed 22 Jul 2021 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,650 at $0.00 | filing |
| 25 May 2021filed 27 May 2021 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Code M | $16K8,333 at $1.89 | filing |
| 25 May 2021filed 27 May 2021 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Sold | $104K3,110 at $33.53 | filing |
| 25 May 2021filed 27 May 2021 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Sold | $105K3,088 at $34.11 | filing |
| 25 May 2021filed 27 May 2021 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Sold | $62K1,736 at $35.45 | filing |
| 25 May 2021filed 27 May 2021 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K399 at $36.09 | filing |
| 25 May 2021filed 27 May 2021 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,333 at $0.00 | filing |
| 14 Jun 2018filed 18 Jun 2018 | Aevi Genomic Medicineoption or derivative | SEC FORM 4 Code A | —238,000 at $0.00 | filing |
| 14 May 2018filed 16 May 2018 | Aevi Genomic Medicineoption or derivative | SEC FORM 4 Code A | —270,000 at $0.00 | filing |
| 11 Aug 2017filed 16 May 2018 | Aevi Genomic Medicineoption or derivative | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 11 Aug 2017filed 15 Aug 2017 | Aevi Genomic Medicineoption or derivative | SEC FORM 4 Code A | —380,000 at $0.00 | filing |
News
Brian Piperthealpenanews.com · 12 Sep 2026Reviewing Arbutus Biopharma (NASDAQ:ABUS) & Prelude Therapeutics (NASDAQ:PRLD)PRLD · tickerreport.com · 17 Oct 2026
1 headline in the last 90 days name Brian Piper; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.